Company: BLLN
Filing Date: 2025-12-10
Form Type: 10-Q
Source: 0001628280-25-056321
Chunk: 215

Company: BillionToOne, Inc.
Filing Date: 2025-12-10
Form: 10-Q
Item: Part I, Item 1
Chunk 215
---
 revenue of $152.6 million, representing 113% year-over-year growth, with a gross margin of 53% and net loss of $41.6 million. While we have generally incurred losses 

1     Bower, X., Wignall, J., Varga, M. G., Zhu, J., O’Sullivan, M., Searle, N. E., Hong, L. K., Dogruluk, T., Li, Z., Farmer, T. E., Rosas-Linhard, E., Luong, J., Lin, E., Simon, M. E., Tsao, D. S., Bosch, J. R. T., Palmer, G., Gajra, A., Huynh, C., & Zhou, W. (2025). Validation of a liquid biopsy assay with increased sensitivity for clinical comprehensive genomic profiling. The Journal of Liquid Biopsy, 100322.

2     More than 50% more actionable/reportable mutations when compared to the comparator products in the aggregate. Actual percentages may vary depending on the individual comparator test.

28

since inception, and had an accumulated deficit of $280.7 million as of September 30, 2025, we had net income of $1.5 million for the nine months ended September 30, 2025 compared to a net loss of $30.1 million for the nine months ended September 30, 2024. During the nine months ended September 30, 2025, we generated revenue of $209.1 million, representing 95% year-over-year revenue growth as compared to the nine months ended September 30, 2024 with a gross margin of 67%. This translated to a non-GAAP income from operations of $15.3 million for the nine months ended September 30, 2025 compared to a non-GAAP loss from operations of $29.4 million for the nine months ended September 30, 2024, which represented an improvement of approximately $44.7 million.

On November 7, 2025, we closed our initial public offering (“IPO”) of our Class A common stock, in which the Company issued and sold 5,233,765 shares of its Class A common stock, which includes the exercise in full of the underwriters’ option to purchase an additional 682,665 shares of Class A common stock, at a public offering price of $60.00 per share. The